Tobramycine absorptie bij SDD
Completed
- Conditions
- Selective Decontamination of the Digestive tract (SDD), Intensive Care Unit (ICU)
- Registration Number
- NL-OMON24557
- Lead Sponsor
- Martini Ziekenhuis, Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
Signed Informed Consent
- Patient has to lie on the ICU or Medium Care ICU
Exclusion Criteria
- Patients that are admitted to the burns ICU
- Patients concurrently or within 72 hours prior to SDD treatment receiving tobramycin administered parenterally or pulmonary
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achieving high (> 1,0 mg/L) tobramycin serum concentrations during the use of SDD.
- Secondary Outcome Measures
Name Time Method Identification of risk factors that contribute to high systemic serum tobramycin concentrations. To this end, we extract data from the patient record in Chipsoft.